Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
NeuroSigma Invests $1Million in 2nd Gen Monarch eTNS Manufacturing
NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating pediatric attention-deficit/hyperactivity disorder (ADHD). NeuroSigma’s manufacturing partner for the project is Singapore-based Armstrong Asia, a leading manufacturer for the medical, automotive and consumer electronics industries, with operations across Asia and partnerships around the globe. The investment was led by Checkmate Capital, a strategic advisory and investment group headquartered in Pasadena, California. The investment and manufacturing project are part of a collaboration between Armstrong and Checkmate, stemming from their July 2025 strategic memorandum of understanding (MOU) focused on the development and manufacturing of new technologies, particularly in the medical device industry.
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
Rona Therapeutics, a clinical-stage RNAi company, announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment. Cohort 1 was completed successfully with a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona’s INHBE program.
Dilon Technologies Gets FDA Approval for MarginProbe 2 Launch
Dilon Technologies, a leading provider of medical devices, has gained FDA approval for its MarginProbe 2 system and is announcing its launch in the U.S. This is the next-generation device for real-time intraoperative margin assessment in breast cancer surgery. MarginProbe 2 is designed to help surgeons achieve greater precision during breast-conserving surgeries, reducing the need for additional procedures and improving patient outcomes.
Link Cell Therapies Launches to Advance CAR-T Cancer Treatments
Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. , with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.
NeuraLight Unveils Scientific Leaders Advancing Neurology
NeuraLight, a company focused on developing precision biomarkers for neurological diseases, has announced the appointment of Nobel Prize winning neuroscientist Professor Thomas Südhof as Scientific Co founder and member of its Scientific Advisory Board. The announcement follows the recent confirmation that Professor Olivier Rascol, a globally recognized neurologist and one of the architects of the MDS UPDRS scale for Parkinson’s disease progression, will serve as Chair of the Scientific Advisory Board.
To share your insights, please write to us at sudipto@intentamplify.com
